3clpro

PF-07321332 is a potent and orally active inhibitor of SARS-CoV 3C-like protease (3CLPRO) .

GRL-0496 is a potent inhibitor with an enzyme inhibitory activity against SARS-CoV 3CLpro with an IC50 of 30 nM and antiviral potency with an EC50 value of 6.9 μM.

GC376 is an inhibitor of 3C-like proteases (3CLpro) with IC50 values range from 0.49~4.35 μM.

PF-00835231 is a CoV-2 cysteine 3C-like protease (3CLpro) inhibitor, with IC50s of 0.27 nM and 4 nM for SARS CoV-2 and SARS CoV-1 3CLpro, respectively. PF-00835231 is the active compound of the first anti-3CLpro regimen in clinical trials.

SARS-CoV-2 3CLpro-IN-16 is a covalent inhibitor of SARS-CoV-2 3CLpro activity, exerting its effect by forming a covalent bond with Cys145.

SARS-CoV-2 3CLpro-IN-20 is a covalent inhibitor of SARS-CoV-2 3CLpro with an IC50 of 0.43 μM and potential antiviral activity.

3CLPro-IN-3 (Compound A36) is an inhibitor of SARS-CoV-2 3CLpro with an IC50 value of 51.3 nM. It exhibits antiviral activity against human coronaviruses 229E, OC43, and the murine coronavirus MHV.

SARS-CoV-2 3CLpro-IN-28 (Compound 19) is an inhibitor of SARS-CoV-2 3CLpro, exhibiting an IC50 value of 0.018 μM.

SARS-CoV-2 3CLpro-IN-30 (compound 29) is a potent inhibitor of the SARS-CoV-2 3CL protease (SARS-CoV-2 3CLpro), with an IC50 of 0.04 μM and an EC50 of 0.3 μM.

SARS-CoV-2 3CLpro-IN-32 (compound B16) is a potent inhibitor of the SARS-CoV-2 3CLpro enzyme, with an IC50 of 0.109 μM. It also demonstrates antiviral activity against the coronavirus HCoV-OC43, with an EC50 of 1.99 μM.

SARS-CoV-2 3CLpro-IN-22 (Compound 17) is an inhibitor of cathepsin L (CTSL) with an IC50 value of 32.5 nM, useful in research related to the SARS-CoV-2 virus.

SARS-CoV-2 3CLpro-IN-23 (CompoundCd3) is a compound isolated from flat lemon (Citrus depressa). It exhibits strong inhibitory activity against the SARS-CoV-2 spike protein with a KD of 0.79 μM. This compound can bind to key amino acid residues, disrupting the formation of the spike protein and h-ACE2 complex.

SARS-CoV-2 3CLpro-IN-31 (Compound 13c) is a potent inhibitor of the SARS-CoV-2 3CL protease (3CLpro) with an IC50 value of 37.33 nM. It effectively obstructs the cleavage of viral polyproteins and subsequently inhibits the replication of SARS-CoV-2. This compound holds promise for research into SARS-CoV-2 infections.

SARS-CoV-2 3CLpro-IN-33 (Compound 16) is an orally active inhibitor of the SARS-CoV-2 3CL protease, with an IC50 value of 1.5 nM. It demonstrates excellent antiviral activity against SARS-CoV-2 in an HEK293T-AT cell model, with an EC50 value of 0.017 μM. SARS-CoV-2 3CLpro-IN-33 is applicable in COVID-19 infection research.

SARS-CoV-2 3CLpro-IN-34 (Compound 55) is a highly effective non-covalent inhibitor of the SARS-CoV-2 3CLpro protease, with an IC50 of 1.9 μM. It also inhibits the SARS-CoV-1 3CL protease, displaying an IC50 of 3.2 μM, and shows strong selectivity for host cysteine proteases such as cathepsins L/K and calpain. Furthermore, SARS-CoV-2 3CLpro-IN-34 exhibits antiviral activity in SARS-CoV-2 infected cells, with an EC50 of 25 μM, is unaffected by P-gp inhibitors, and does not cause significant cytotoxicity. This compound can be utilized in the study of SARS-CoV-2 infections.

SARS 3CLpro-IN-1 (Compound 3b) is a stereo-specific SARS 3CL protease inhibitor from the octahydroisochromene scaffold, exhibiting inhibition of the P1 site imidazole with an IC50 value of 95 μM [1].

SARS-CoV-2 3CLpro-IN-4 (Compound 5g) is a multifunctional inhibitor of SARS-CoV-2 3CLpro with antiviral, antibacterial, and antifungal properties.

SARS-CoV-2 3CLpro-IN-2 is a potent inhibitor of the 3CL protease pair, demonstrating significant research potential for SARS-CoV-2 disease.

SARS-CoV-2 3CLpro-IN-1 (Compound 14c) is a highly potent inhibitor specifically designed to target and inhibit the activity of SARS-CoV-2 3CL pro, a cysteine protease found in the main coronaviruses. This enzyme is a promising target for antiviral drug development, positioning SARS-CoV-2 3CLpro-IN-1 as significant for advancing research in infectious diseases [1].

SARS-CoV-2 3CLpro-IN-3, a SARS-CoV-2 3CLpro inhibitor, demonstrates antiviral, antibacterial, and antifungal properties.

SARS-CoV-2 3CLpro-IN-10(5d) is a potent inhibitor of the SARS-CoV-2 3CL protease with an IC50 value of 190 nM and demonstrates broad-spectrum antiviral activity, exhibiting IC50 values of 790 nM for SARS-CoV-1 and 70 nM for MERS-CoV.

SARS-CoV-2 3CLpro-IN-11(11d) is a broad-spectrum antiviral compound that inhibits the SARS-CoV-2 3CL protease with an IC50 of 140 nM, and also exhibits inhibitory activity against SARS-CoV-1 and MERS-CoV with IC50 values of 240 nM and 70 nM, respectively.

SARS-CoV-2 3CLpro-IN-5 is a covalent inhibitor targeting the 3C-like protease (3CLpro), with potent inhibitory activity (IC50: 3.8 nM) and 9.0% oral bioavailability (BA), used in COVID-19 research [1].

SARS-CoV-2 3CLpro-IN-6 is a reversible covalent inhibitor of the SARS-CoV-2 3CL protease, showing potent inhibitory activity with an IC50 of 4.9 μM, and is used in the research of coronavirus disease 2019 (COVID-19).